CORCEPT THERAPEUTICS INC — Form 8-K
Filed September 23, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
Sean Maduck, President of Corcept's Endocrinology division for 14 years, is retiring effective September 23, 2026. Justin Gunn, who joined Corcept in July 2024 as Vice President of Sales for Oncology, will assume the role starting October 1, 2026, and will join the Executive Team reporting to CEO Joseph Belanoff. Maduck will remain as a senior commercial advisor to support transition.
Why this rating
Internal promotion of 2-year employee to divisional president is standard succession; no financial impact disclosed. Endocrinology is core business, but transition risk mitigated by retention advisor and continuity focus.
See more from September 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.